Milder nausea and reduced appetite are the tier it says to monitor
Contact your healthcare provider immediately if you experience: Signs of pancreatitis severe, persistent abdominal pain (often radiating to the back), with or without vomiting Symptoms of gallbladder disease right upper abdominal pain, fever, jaundice (yellowing of skin or eyes) Severe dehydration or signs of acute kidney injury decreased urination, extreme thirst, dizziness, confusion, or rapid heartbeat Hypoglycemia symptoms (especially if taking insulin or sulfonylureas) shakiness, sweating, confusion, rapid heartbeat Any sudden vision changes blurred vision or other visual disturbances Allergic reactions difficulty breathing, facial swelling, severe rash, or hives (seek emergency care immediately) Signs of thyroid tumors neck lump, persistent hoarseness, difficulty swallowing, or shortness of breath Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use Zepbound, as tirzepatide carries a boxed warning regarding thyroid C-cell tumors observed in animal studies
The primary outcome was a new diagnosis of SIBO following GLP-1 RA exposure
The co-culture system established with MCECs and MPMs is shown in Figure 4D
Tirzepatide (sold as Mounjaro and Zepbound) is a dual GIP/GLP-1 receptor agonist made by Eli Lilly
